Crossmark

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Crossref DOI link: https://doi.org/10.1038/sigtrans.2016.2

Published Online: 2016-03-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Wen-ying

Wang, Yao

Guo, Ye-lei

Dai, Han-ren

Yang, Qing-ming

Zhang, Ya-jing

Zhang, Yan

Chen, Mei-xia

Wang, Chun-meng

Feng, Kai-chao

Li, Su-xia

Liu, Yang

Shi, Feng-xia

Luo, Can

Han, Wei-dong
License Information

Text and Data Mining valid from 2016-03-11

Version of Record valid from 2016-03-11
More Information

Article History

Received: 18 November 2015

Revised: 11 January 2016

Accepted: 14 January 2016

First Online: 11 March 2016

Competing interests

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below